Novel iodine radiolabelled PARP inhibitor (rPARPi) entering clinical development in Phase 1 trial to assess safety and early efficacy Dose escalation study followed by expansion cohorts in recurrent glioblastoma with potential to move into primary glioblastoma BERLIN, July 25, 2024…